- Product Details
Keywords
- Orforglipron intermediate
- commerical production
- Factory supply
Quick Details
- ProName: (4-Fluoro-3,5-dimethylphenyl)hydrazine...
- CasNo: 2212021-40-2
- Appearance: white powder
- Application: Orforglipron intermediate
- PackAge: 25kg/drum
- Port: Shanghai or instructed by customer
- ProductionCapacity: 100 Kilogram/Month
- Purity: 98%
- Storage: keep in room temperature
- Transportation: by Air/Sea
- LimitNum: 1 Gram
Superiority
Product Name:Orforlipron intermediate
CAS:2212021-40-2
Molecular formula: C8H12ClFN2
Molecular weight:190.65
Details
Nantong Noatic Bio-pharm Technology Co., Ltd. was established in 2015,and is a high-tech company, it has passed ISO19001 system certification, the headquarter located in Biomedical innovation Park, Haimen District, Nantong City, Jiangsu Province, and has a research and development center of over 3000 square meters.
Noatic’s main business focuses on the development of generic drug intermediates and APIs, and provides supporting registration and declaration services for pharmaceutical factories. In addition, Noatic can undertake CRO and CDMO projects, and is actively engaged in the development of ADC intermediates and oligonucleotide drugs.
Its wholly-owned subsidiary, Shandong Elite Bio-Pharm, was established in 2019, located in the provincial -level chemical park in Shanghe, Jinan City, Shangdong province, it has built 3 production workshops ,the subsidiary has passed the ISO System certification and carries out quality management according to GMP requirement. Its production capabilities include various types of chemical synthesis such as high temperature, ultra-low temperature and hydrogenation So far, Nantong Noatic and Elite have established cooperative relationships with listed domestic pharmaceutical companies, as well as pharmaceutical companies in India and Europe and America, and we have successfully passed the customers’ audits. Noatic adheres to high quality and professional service concepts, committed to providing quality service in the biopharmaceutical industry.